These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 2743869

  • 21. In vitro activity of a new quinolone, rufloxacin, against nosocomial isolates.
    Mattina R, Cocuzza CE, Cesana M, Bonfiglio G.
    Chemotherapy; 1991; 37(4):260-9. PubMed ID: 1665122
    [Abstract] [Full Text] [Related]

  • 22. [Fluoroquinolones--antibacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs].
    Naumann P, Dopp C.
    Internist (Berl); 1989 Jan; 30(1):20-31. PubMed ID: 2646237
    [No Abstract] [Full Text] [Related]

  • 23. Ocular pharmacokinetics of rufloxacin a new fluoroquinolone antibiotic.
    Nucci P, Lombardo N, Cremonesi F, Manitto MP, Brancato R, Ghione M.
    Clin Ter; 1992 Jun; 140(6):563-7. PubMed ID: 1322259
    [Abstract] [Full Text] [Related]

  • 24. In vitro activities of irloxacin and E-3846, two new quinolones.
    García-Rodríguez JA, García Sánchez JE, Muñoz Bellido JL, Trujillano I.
    Antimicrob Agents Chemother; 1990 Jun; 34(6):1262-7. PubMed ID: 2393288
    [Abstract] [Full Text] [Related]

  • 25. Antimicrobial activity of E-4441, a representative azetidine quinolone.
    Esteve M, Moros M, Coll R, Xicota MA, Llovera S.
    Drugs Exp Clin Res; 1990 Jun; 16(9):445-9. PubMed ID: 2100245
    [Abstract] [Full Text] [Related]

  • 26. [Refractory respiratory tract infections. 7. Trends in the development of new chemotherapeutic agents for respiratory tract infections. b. Synthetic antibacterial agents].
    Ohno I, Ida S.
    Nihon Rinsho; 1987 Mar; 45(3):577-82. PubMed ID: 3298736
    [No Abstract] [Full Text] [Related]

  • 27. In vitro and in vivo antibacterial activities of E-4497, a new 3-amine-3-methyl-azetidinyl tricyclic fluoroquinolone.
    Gargallo-Viola D, Esteve M, Llovera S, Roca X, Guinea J.
    Antimicrob Agents Chemother; 1991 Mar; 35(3):442-7. PubMed ID: 2039195
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of OPC-17116 against important pathogens that cause respiratory tract infections.
    Wakebe H, Imada T, Yoneda H, Mukai F, Ohguro K, Ohmori K, Tamaoka H, Yabuuchi Y.
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2340-5. PubMed ID: 7840567
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Fluoroquinolones: pharmacology, antibacterial spectrum and indications in pneumology].
    Underner M, Grignon B, Roblot F, Meurice JC, Patte F.
    Rev Pneumol Clin; 1989 Oct; 45(1):14-22. PubMed ID: 2662344
    [Abstract] [Full Text] [Related]

  • 33. The role of fluoroquinolones in the management of skin, soft tissue, and bone infections.
    Fong IW.
    Clin Invest Med; 1989 Feb; 12(1):44-9. PubMed ID: 2646054
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 23.